Subsequently, the 2022 NCCN guidelines incorporated the use of 68Ga-PSMA-11 and 18F-DCFPyL PET/CT and PET/MR for detecting recurrences, since PSMA PET ligands present better sensitivity and specificity than conventional imaging (CT or MRI) for detecting micro-metastatic prostate cancer [98]. Here, FOLH1 is linked to metastatic prostate carcinoma.